Trials / Completed
CompletedNCT01484600
Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of REGN668 Administered Subcutaneously to Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This is a study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of REGN668 Administered Subcutaneously to Healthy Volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | REGN668: Injection Rate 1 | Subjects will receive REGN668 via SC injection |
| DRUG | REGN668: Injection Rate 2 | Subjects will receive study drug via alternate delivery (if necessary) |
Timeline
- Start date
- 2011-12-01
- Primary completion
- 2012-02-01
- Completion
- 2012-02-01
- First posted
- 2011-12-02
- Last updated
- 2012-03-14
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01484600. Inclusion in this directory is not an endorsement.